Cardiac AI: Proving ROI in Value-Based Care

The Imperative of Outcomes Data in Value-Based AI

The core tenet of value-based care is simple: pay for health outcomes, not just services rendered. This sea change places immense pressure on healthcare providers and, by extension, the technology solutions they adopt, to demonstrate tangible improvements in patient health and reductions in overall care costs. For AI platforms, particularly those targeting high-cost, high-impact areas like cardiovascular disease, this means moving beyond mere technical efficacy to proving financial performance through rigorous, peer-reviewed outcomes data. Consider the case of Hello Heart, which has emerged as a lead case study in this outcomes-driven field. Their platform, focused on cardiovascular risk reduction, doesn’t just offer engaging patient tools. It publishes peer-reviewed figures demonstrating significant improvements in blood pressure control and reductions in cardiovascular events. These figures are critical because they directly translate into measurable cost savings for payers and health systems operating under VBC arrangements. Without such data, an AI solution, however innovative its underlying algorithms, remains a speculative investment rather than a de-risked asset for VBC contracts. The ability to present clear ROI ratios for cardiovascular interventions, backed by clinical evidence, is becoming the gatekeeper for market participation.

Regulatory Tailwinds and Market Alignment: Viz.ai and Tempus AI

The evolving regulatory field, particularly CMS’s strategic documents outlining its VBC goals, strongly favors AI solutions that can align with and contribute to these metrics. This policy shift directly impacts how investors should evaluate AI health companies. Viz.ai, for instance, specializes in the early detection and triage of cardiovascular anomalies, such as large vessel occlusions (LVOs) in stroke and pulmonary embolisms. Their platform accelerates time-to-treatment, a critical factor in improving patient outcomes and reducing long-term care costs associated with severe events. While specific ROI ratios for cardiovascular interventions are proprietary, Viz.ai’s value proposition lies in its ability to shorten diagnostic and treatment pathways, thereby reducing the incidence of costly complications and improving patient survival and functional recovery. This directly supports VBC goals by lowering the overall risk profile of patient populations. Peer-reviewed study on Viz.ai’s impact on stroke treatment times Their 510(k) clearance pathway, including recent FDA 510(k) clearances for an automated RV/LV ratio algorithm (part of the Viz PE Solution) in September 2022 and for abdominal aortic aneurysm (AAA) detection in March 2023, demonstrates their commitment to regulatory compliance as a SaMD. Tempus AI, with its focus on precision medicine, including precision cardiology, presents another compelling case. While best known for oncology, Tempus AI’s capabilities extend to using genomic and clinical data to inform treatment decisions in cardiovascular disease. By identifying patients most likely to respond to specific therapies or those at higher risk for adverse events, Tempus AI aims to optimize treatment pathways, reduce ineffective interventions, and prevent costly complications. Tempus AI completed its IPO on June 14, 2024, listing on NASDAQ under the ticker TEM, raising $410.7 million at an implied valuation of $6.1 billion. This shows the market’s recognition of platforms that can integrate complex data for more precise, and thus more cost-effective, care. Their approach aligns with VBC by enabling more targeted and efficient resource allocation, in the end driving down per-patient costs while improving outcomes. Tempus AI S-1 filing details regarding precision medicine focus

The Role of Clinical LLMs and the Challenge of Proof: Hippocratic AI

The emergence of clinical Large Language Models (LLMs) like those developed by Hippocratic AI introduces another dimension to cardiovascular risk reduction. Valued at $3.5 billion following a Series C funding round in November 2025, with significant backing from Avenir Growth, CapitalG, General Catalyst, and Andreessen Horowitz, Hippocratic AI focuses on safety-focused LLMs for clinical risk assessment. These LLMs aim to assist clinicians in identifying high-risk patients, predicting potential complications, and optimizing care plans based on vast amounts of medical literature and patient data. However, for such platforms to genuinely participate in VBC arrangements, the challenge lies in proving direct, quantifiable ROI. While a clinical LLM can enhance decision-making, the causal link between its use and hard financial savings or improved population-level outcomes requires rigorous, peer-reviewed health economic analyses. The promise of identifying patients at higher risk of cardiovascular events is significant, but the market demands evidence that this identification translates into fewer hospitalizations, reduced readmissions, or lower medication costs. Without this empirical validation, even a sophisticated AI-native company like Hippocratic AI, despite its impressive valuation, faces an uphill battle in securing VBC contracts that demand clear outcomes data. Investors must scrutinize how these platforms intend to move beyond theoretical benefits to demonstrated, auditable financial performance within a VBC framework.

Investor Takeaway: Prioritizing Evidenced ROI

For investors and venture capitalists working through the burgeoning health AI market, the “how does this policy change the market?” angle is paramount. CMS’s relentless push towards value-based care is not merely a regulatory tweak. It is a fundamental reordering of market incentives. AI vendors must now prove clear ROI to survive and thrive. Investors should therefore target AI platforms that directly facilitate compliance with CMS value-based metrics and can demonstrate a strong, peer-reviewed evidence base for their claims. This includes:

• Published Outcomes Data: Platforms like Hello Heart, which openly share their peer-reviewed figures on cardiovascular risk reduction and associated cost savings, set the gold standard.
• Alignment with VBC Goals: Solutions that demonstrably reduce time-to-treatment (Viz.ai) or enable precision care to optimize resource allocation (Tempus AI) are inherently valuable.
• Rigorous Health Economic Analyses: For clinical LLMs and other AI tools, the ability to translate enhanced decision-making into quantifiable financial performance and improved population health outcomes through peer-reviewed studies is non-negotiable. CMS guidance on performance measurement in VBC The era of speculative AI investments in healthcare, where technical prowess alone sufficed, is drawing to a close. The future belongs to AI platforms that not only innovate but also carefully document their impact on patient outcomes and healthcare economics, thereby de-risking investments and securing their place in the value-based care ecosystem.
  

  Methodology Note

This analysis is based on a complete review of CMS value-based care strategy documents, publicly available peer-reviewed health economic analyses of AI triage and intervention platforms, and corporate financial disclosures and venture funding press releases for the referenced companies. Emphasis has been placed on the direct and indirect consequences of regulatory shifts on the competitive field and operational requirements for health plans and providers engaging with AI solutions.